New study prepares those with genetic clot risk for future trials
NCT ID NCT07584265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study enrolls 100 adults who have or may have Factor V Leiden or Prothrombin G20210A mutations, which increase the risk of blood clots. Participants undergo genetic testing to confirm their status, then attend a site visit for basic health checks like blood pressure, ECG, and blood tests. The goal is to establish a health baseline and familiarize participants with the clinical trial environment, so they can join future studies. The study lasts about 10 weeks and includes 1-2 visits and a follow-up call.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help prepare participants for future clinical trials aimed at preventing blood clots in people with these genetic mutations.
- What could go wrong
- This is an early engagement study, not a treatment trial. It does not test any new therapy, so there is no direct health benefit for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR V LEIDEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Richmond Pharmacology Limited
RECRUITINGLondon, SE1 1YR, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.